Cargando…
Hormesis in cancer immunology: Does the quantity of an immune reactant matter?
We recently reported that tumor-directed antibodies could either stimulate, or inhibit, tumor progression, dependent upon the dosage used. The narrow range over which this immune response curve (IRC) occurs is surprising. Here we discuss features of the IRC, the mechanisms identified so far, and the...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108457/ https://www.ncbi.nlm.nih.gov/pubmed/25083340 http://dx.doi.org/10.4161/onci.29312 |
_version_ | 1782327761234296832 |
---|---|
author | Pearce, Oliver MT Läubli, Heinz Bui, Jack Varki, Ajit |
author_facet | Pearce, Oliver MT Läubli, Heinz Bui, Jack Varki, Ajit |
author_sort | Pearce, Oliver MT |
collection | PubMed |
description | We recently reported that tumor-directed antibodies could either stimulate, or inhibit, tumor progression, dependent upon the dosage used. The narrow range over which this immune response curve (IRC) occurs is surprising. Here we discuss features of the IRC, the mechanisms identified so far, and the potential clinical implications. |
format | Online Article Text |
id | pubmed-4108457 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Landes Bioscience |
record_format | MEDLINE/PubMed |
spelling | pubmed-41084572014-07-31 Hormesis in cancer immunology: Does the quantity of an immune reactant matter? Pearce, Oliver MT Läubli, Heinz Bui, Jack Varki, Ajit Oncoimmunology Author's View We recently reported that tumor-directed antibodies could either stimulate, or inhibit, tumor progression, dependent upon the dosage used. The narrow range over which this immune response curve (IRC) occurs is surprising. Here we discuss features of the IRC, the mechanisms identified so far, and the potential clinical implications. Landes Bioscience 2014-06-25 /pmc/articles/PMC4108457/ /pubmed/25083340 http://dx.doi.org/10.4161/onci.29312 Text en Copyright © 2014 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Author's View Pearce, Oliver MT Läubli, Heinz Bui, Jack Varki, Ajit Hormesis in cancer immunology: Does the quantity of an immune reactant matter? |
title | Hormesis in cancer immunology: Does the quantity of an immune reactant matter? |
title_full | Hormesis in cancer immunology: Does the quantity of an immune reactant matter? |
title_fullStr | Hormesis in cancer immunology: Does the quantity of an immune reactant matter? |
title_full_unstemmed | Hormesis in cancer immunology: Does the quantity of an immune reactant matter? |
title_short | Hormesis in cancer immunology: Does the quantity of an immune reactant matter? |
title_sort | hormesis in cancer immunology: does the quantity of an immune reactant matter? |
topic | Author's View |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108457/ https://www.ncbi.nlm.nih.gov/pubmed/25083340 http://dx.doi.org/10.4161/onci.29312 |
work_keys_str_mv | AT pearceolivermt hormesisincancerimmunologydoesthequantityofanimmunereactantmatter AT laubliheinz hormesisincancerimmunologydoesthequantityofanimmunereactantmatter AT buijack hormesisincancerimmunologydoesthequantityofanimmunereactantmatter AT varkiajit hormesisincancerimmunologydoesthequantityofanimmunereactantmatter |